The EBMT Paediatric Diseases Working Party and the first ESH–EBMT training course on blood and marrow transplantation in children

Dini, Giorgio

doi:10.1038/bmt.2008.44

Cited by 1 publication

(2 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With a small scale of patients, these centers may lack experience with HSCTs, in particular using HSCs from unrelated donors to treat non-malignant diseases. Dini agrees with our opinions and believes that a center must carry out at least 10 allogeneic HSCTs each year to train a high-quality, skilled HSCT team (16).…”

Section: Discussionsupporting

confidence: 74%

“…Recently, Pediatric Diseases Working Party analyzed the risk factors for transplant‐related mortality and believes that children, unlike adolescents or adults, require special care by experienced staff. Treatment at highly skilled pediatric centers has been shown to improve survival of pediatric patients . With a small scale of patients, these centers may lack experience with HSCTs, in particular using HSCs from unrelated donors to treat non‐malignant diseases.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Pediatric hematopoietic stem cell transplantation in China: Data and trends during 1998–2012

Chen

Qin

et al. 2015

Pediatric Transplantation

View full text Add to dashboard Cite

The success of treating a wide variety of pediatric diseases with HSCT, hematologic malignancies in particular, has resulted in an increased number of long-term survivors. This study is the first large-scale, multicentre report that describes the evolution of pediatric HSCTs in China during the period of 1998-2012. Of all 1052 patients, 266 cases were treated with autologous HSCs and 786 used allogeneic HSCs. The disease indications for HSCTs mainly included leukemias, lymphoma, solid tumors, and non-malignant disorders. The total number of HSCTs, especially unrelated donor transplants, appeared to be increasing year by year. For patients with neuroblastoma, the therapeutic efficacy seemed to be poor, with a five-yr OS and DFS rate of 34.5 ± 14.3% and 20.7 ± 9.6%, respectively. In contrast, the survival of patients with SAA was prominently improved, and their five-yr OS and DFS rates were 82.8 ± 4% and 80.7 ± 4.1%, respectively. Patients who received cord blood transplants had a lower incidence of acute GVHD than that of PB and/or BM transplants from unrelated donors. This report offers us a valuable resource for evaluating the changes in HSCTs in China over the past 14 yr.

show abstract

Section: Discussionsupporting

confidence: 74%

Section: Discussionmentioning

confidence: 99%